An interventional study of Genetic, molecular and/or omics analyses in Chronic Leukemia, Acute Leukemia and Myeloproliferative Disorders, sponsored by Azienda Ospedaliero-Universitaria di Parma. Recruiting at 1 site in Italy. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Azienda Ospedaliero-Universitaria di Parma · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Myeloproliferative Disorders with a site in Italy — 14 open to participants now, 26 under way, 5 of them phase 3. Myeloproliferative Disorders · Italy.
Among the 68 studies in Myeloproliferative Disorders with a site in Italy, this one is the 16th largest by planned enrollment of the 54 interventional ones that give a count, is one of 10 that started in 2021, is one of 8 with no phase, reaches primary completion later than 6 of the 25 other live ones, and was the 64th registered.
668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.
Browse Myeloproliferative Disorders studies →14 of the 68 studies in Myeloproliferative Disorders with a site in Italy are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
Prelude Therapeutics Incorporated · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
Incyte Corporation · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
Azienda Ospedaliero-Universitaria di Parma · Sites in Italy
Ages 2+
Azienda Ospedaliero-Universitaria di Parma · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 25 · Phase 3 14 · Phase 4 1
First in 2000; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 47 across 463 interventional studies indexed under Myeloproliferative Disorders.
Median enrollment 145 across the 54 interventional studies, 442 across the 13 observational. Of the 38 that completed or were terminated, 23 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 68 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero-Universitaria di Parma is the lead sponsor of 44 studies on the registry; 13 are open to participants now.
Azienda Ospedaliero-Universitaria di Parma has 4 studies filed under Myeloproliferative Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Myeloproliferative Disorders with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01761968ItalfarmacoLong-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | 2026-12 |
| NCT05553873University of Milano BicoccaEvaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study. | 2026-12 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT07403630Azienda Ospedaliero-Universitaria di ParmaINTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) | 2027-02 |
| NCT07419178Azienda Ospedaliero-Universitaria di ParmaA New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept | 2027-02-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 68 studies in Myeloproliferative Disorders with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.
The hematological malignancies are referred to all the different hematological entities according to WHO 2016 Classification such as acute (AML, ALL) or chronic leukemia (CLL, CML, HCL), myeloproliferative or lymphoproliferative disorders (MF, PV, TE, CMML, NHL, HL) and myelodysplastic or myelodysplastic/myeloproliferative disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with hematological malignancies either treatment free or relapsed/ refractory
Other: Genetic, molecular and/or omics analyses
The focus of our scientific approach is based on genetic, molecular and/or omics analyses performed with new technologies (Nanostring, NGS, single cell technologies, radiomics)
To evaluate the anti-cancer activity of bio-active compounds and derivatives present in FDA/EMA approved or investigator provided libraries, investigational molecules
The study will be performed in malignant cells of a cohort of 250 patients with onco-hematological disorders obtained from a bone marrow aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from rachicentesis, tissue aspirate etc. separated by a tissue-specific protocol: densitometry protocol for peripheral or bone marrow blood, tissue fractionation for tissue biopsies, precipitation for liquor. Cells will be than cultured in the presence or absence of small molecules derived from chemical library FDA/EMA approved, investigational molecules (monoclonal antibodies, antibody-drug conjugate, other experimental compounds). We will use miniaturized assays such cell culture in 384 multiwell plates to maximize the use of primary cells and to test simultaneously multiple concentrations of multiple drugs. We will perform several assays to assess cellular response to drug's perturbation such as: proliferation, cell cycle and apoptosis analysis
Time frame: At baseline
To characterize molecular biomarkers for the identification of novel target therapies
Thanks to genetic and molecular and/or omics analyses performed with new technologies (Nanostring, NGS, single cell technologies, radiomics), we propose to study novel molecular target that may be sensitive to the tested compounds in order to identify new target therapies.
Time frame: At baseline
Correlate anti-cancer response with diagnostic (WHO classification) and molecular or novel omics features including cytogenetics, genomics, next generation or single cell technologies, radiomics.
The completion of experiments described in aim 1 will give us the opportunity, for example, to extrapolate the IC50 (half maximal inhibitory concentration: a measure of the effectiveness of a substance in inhibiting a specific biological or biochemical function) dose for a small molecule of interest and correlate this value with clinical, cytogenetic, genomic and molecular features of that particular case. These data will be further compared with larger repository publicly available in the literature.
Time frame: At baseline
Started Jul 2021 (actual). Primary completion is estimated for Jul 2026, 60 months after the start.
Of 26 interventional studies with no phase under Myeloproliferative Disorders, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 128. This study's planned 60 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myeloproliferative Disorders →
Azienda Ospedaliero-Universitaria di Parma